Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathwa...
Main Authors: | Silvia Sookoian, Carlos J. Pirola |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2020-10-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-2020-0136.pdf |
Similar Items
-
Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications
by: Maria Sotiropoulou, et al.
Published: (2021-01-01) -
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity
by: Silvia Sookoian, et al.
Published: (2009-10-01) -
Recent research trends and updates on nonalcoholic fatty liver disease
by: Jeong-Ju Yoo, et al.
Published: (2019-03-01) -
Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
by: Apollinariya V. Bogolyubova, et al.
Published: (2017-12-01) -
Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
by: Filip R, et al.
Published: (2018-10-01)